EFFECTORBIO, INC.

Davis, CA · Biotech · Defunct

Rationally engineered antimicrobial peptides (AMPs) to treat multidrug-resistant bacterial infections

Grants
$956K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · 1R43HL140740 - 01A1$308,160
Federal grantDepartment of Health and Human Services · Phase I · Tackling the MARCKS-PIP3 Circuit to Attenuate Chronic Pulmonary Fibrosis$347,749
Federal grantDepartment of Health and Human Services · Phase I · Novel antimicrobials in fighting carbapenem-resistant Klebsiella pneumoniae$300,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2278Dren Bio, Inc.—$93M
2279CURAVAC, INC.—$4.7M
2280bluebird bio—$179M
2281EFFECTORBIO, INC.——
2282Ensysce Biosciences, Inc.—$103M
2283VIACYTE, INC.—$150M
2284EMULATE THERAPEUTICS, INC.—$12M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.